CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
Oct. 5, 2020—Cepheid received emergency use authorization from the FDA for its Xpert Xpress SARS-CoV-2/Flu/RSV, a rapid molecular diagnostic test for qualitative detection of the viruses that cause COVID-19, flu A, flu B, and RSV infections from a single patient sample.
“Things may get complicated this respiratory season as clinicians encounter a range of viral infections with symptoms overlapping with COVID-19, including flu A, flu B, and respiratory syncytial virus,” David Persing, MD, PhD, chief medical and technology officer at Cepheid, said in a press statement. “The ability to run a single, highly sensitive test that detects all four viruses in a syndromic panel provides actionable results and helps to alleviate pressure on our health care system.”